{'fraction_non_alphanumeric': 0.03855421686746988, 'fraction_numerical': 0.03132530120481928, 'mean_word_length': 5.38974358974359, 'pattern_counts': {'":': 0, '<': 3, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Expression of CDKN2 gene product in human bronchogenic carcinoma].

OBJECTIVE
To examine the expression of P16 protein in bronchogenic carcinoma and normal tissue adjacent to carcinoma and to determine the relationship between the gene and bronchogenic carcinoma.


METHOD
Using a rabbit polyclonal antibody against P16 (N-20), the expression of P16 protein was studied immunohistochemically on formalin fixed, paraffin embedded sections.


RESULTS
The cytoplasmic P16 protein was mainly present in normal bronchial epithelium (93.8%), serous gland (92.6%) and alveolar epithelium (71.4%), the expression levels of P16 were significantly lower in carcinoma tissues (61.9%) when compared to levels in their normal counterparts (P < 0.01). Among tumors, squamous cell carcinomas and small cell carcinomas exhibited lower P16 expression levels compared with adenocarcinomas (P < 0.01). The expression levels of P16 were lower in poorly-differentiated adenocarcinomas compared with those in well-differentiated adenocarcinomas (P < 0.05).


CONCLUSIONS
The results suggested that CDKN2 gene was a tumor suppressor gene, the inactivation of which were involved in the carcinogenesis of bronchogenic carcinoma and implicated in tumor differentiation.